Author(s): Antonini TM, Furlan V, Teicher E, HaimBoukobza S, Sebagh M, , Antonini TM, Furlan V, Teicher E, HaimBoukobza S, Sebagh M,
Abstract Share this page
Abstract We report, for the first time, the outcome of anti-hepatitis C virus (HCV) triple therapy with telaprevir in an HIV/HCV co-infected transplanted patient. After liver transplantation, the patient experienced a severe HCV recurrence with fibrosing cholestatic hepatitis, and anti-HCV therapy with pegylated interferon alpha 2a, ribavirin and telaprevir was initiated. A sustained virological response was achieved after 48 weeks of anti-HCV therapy. Drug-drug interactions between antiretroviral therapy, immunosuppressive agents and anti-HCV therapy could be managed.
This article was published in AIDS
and referenced in Journal of AIDS & Clinical Research